The Product
   
 

What is CholesBlock?

What is it made of?

1. Plant Sterols

2. Sytrinol

Media Support:

Heart Healthy Effects of Sytrinol in Multiple Clinical Trials

The cardioprotective and cholesterol-improving claims for Sytrinol™ are supported by human studies. In the first clinical trial, sixty subjects were divided into six groups and the effects of Sytrinol were measured in men and women diagnosed with high cholesterol and screened to eliminate thyroid disorders, kidney disorders, and diabetes. Subjects were instructed to maintain normal dietary habits and discontinue using vitamins, supplements, and cholesterol-lowering medications for at least six weeks before and during the study. Fasting blood samples were drawn at the onset and at the end of each four-week trial, and plasma lipid profiles and other metabolic parameters were analyzed using standard methods.

The results from the first trial (Graph 1) show that four weeks of treatment with 300 mg of Sytrinol daily significantly improved levels of total cholesterol (-25%), LDL cholesterol (-19%), and triglycerides (-24%). HDL levels were unchanged and body mass remained relatively stable.

Graph 1. Sytrinol Clinical Trial I Results

Means SEM. Statistical analysis by ANOVA plus post test by Dunnett’s method
b – Significantly different within same group, P ≤ 0.05


In the second trial, ten subjects with elevated cholesterol levels benefited after only four weeks of treatment with 300 mg per day of Sytrinol. As shown in Graph 2, treatment with Sytrinol substantially improved levels of plasma total cholesterol (-20%), LDL (-22%), apolipoprotein B (-21%), an important structural protein of LDL, and triglycerides (-28%). Additionally, subjects in the second trial benefited from a significant 5% increase in apolipoprotein A1, an important structural protein of HDL.

Graph 2. Sytrinol Clinical Trial II Results

Means SEM. Statistical analysis by ANOVA plus post test by Dunnett’s method b – Significantly different within same group, P ≤ 0.05

We have completed a longer-term, double-blind, randomized study involving 120 men and women with moderately elevated cholesterol levels (total cholesterol above 230 mg/dL and LDL greater than 155 mg/dL). For 12 weeks, subjects received either 300 mg per day of Sytrinol or a placebo, the results are compelling. As shown in Graph 3, compared to placebo, the Sytrinol subjects observed an improvement of 30% in total cholesterol, 27% in LDL cholesterol, and 34% in total triglycerides. In addition, HDL levels increased 4%, resulting in a significant 29% improvement in the LDL:HDL ratio. The improvement in total cholesterol, LDL cholesterol, and total triglycerides was significant at week 4 and continued through week 12. In some cases, the optimum improvements were seen at week 12 compared to week 4 (Table 1).

Graph 3. Sytrinol Clinical Study III Results

Means SEM. Statistical analysis by ANOVA plus post test by Dunnett’s method
b – Significantly different from placebo group, P ≤ 0.05; significantly different within same group, P ≤ 0.05


Table 1. Results of Sytrinol supplementation on cholesterol levels

Means SEM. Statistical analysis by ANOVA plus post test by Dunnett’s method
*mg/dL
nc – no change from baseline
a – Significantly different from placebo, P ≤ 0.05
b – Significantly different within same group, P ≤ 0.05

Comparing the results of clinical studies I & II with trial III four week data demonstrated that the improvement in total cholesterol, LDL cholesterol, and triglycerides is repeatable in all clinical trials at week 4 (Table 2).

Table 2. Four week results of Sytrinol™ clinical study I, II & III on cholesterol levels

Means SEM. Statistical analysis by ANOVA plus post test by Dunnett’s method
nc – no change from baseline
b – Significantly different within same group, P ≤ 0.05

Conclusion

The benefits of Sytrinol have been shown in vitro, in vivo, and in clinical studies using the same patented formula that consumers can now see on the shelf. Sytrinol requires only 150 mg twice per day and does not have to be taken before, during, or after meals. In multiple clinical trials, Sytrinol has improved total cholesterol up to 30%, improved LDL cholesterol up to 27%, improved total triglyceride up to 34%, improved HDL cholesterol up to 4%, and improved LDL:HDL up to 30%. Some products claim to be clinically proven; however, the ingredient used in the trial is not available to the consumer. Furthermore, too often the effective dose used in the clinical trials is not the same dosage that is found in the supplements on retail shelves. SourceOne provides a consistent and reliable supply of Sytrinol, the same ingredient at the same effective dose used in all clinical trials. Sytrinol is also a powerful antioxidant with numerous heart health benefits including playing a significant role as an anti-inflammatory compound.

 
       
HOME | THE PRODUCT | OUR COMPANY | LEARNING RESOURCES | CONTACT US
Copyright ©2008. CholesBlock, Inc. All rights reserved.